Following 12 weeks of treatment in a biopsy-confirmed, diet-induced obese mouse model of NASH, ALT-801, a GLP-1R/GCGR dual agonist, was shown to significantly lower body weight, plasma cholesterol and liver enzymes, liver weight, liver steatosis, histological markers of inflammation and fibrosis and, importantly, composite NAS, compared to vehicle-treated control. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.